FASN and B-cell chronic lymphocytic leukemia: Dysregulation of fatty acid metabolism in cancer cells is well known [22,23] as it is the potential of fatty acid synthase (FAS) as a drug target; in fact, FAS was expressed above normal in MM [24] and CLL [25,26].